Custom Exosomes Service for RNAi
Exosomes have emerged as novel gene delivery tools owing to their multiple advantages over conventional delivery systems for RNA interference (RNAi). Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs offers top-quality service in the development of exosome-mediated delivery system for RNAi. We are pleased to share our cutting-edge technology and extensive experience in custom exosome service to facilitate our clients' research and project development.
The Biological Superiority of Exosomes for RNAi
The great interest in utilizing exosomes for siRNA and miRNA delivery derives from their unique biological architecture and intrinsic properties. Unlike artificially synthesized nanocarriers, exosomes possess a highly sophisticated lipid bilayer vesicular structure with an aqueous core and a complex lipophilic shell enriched with cholesterol, sphingomyelin, and ceramides.
Figure 1. Overview of exosome modification and targeted delivery.1
Key Advantages of Exosome-Mediated Delivery:
-
Exceptional Biocompatibility & Low Immunogenicity
As natural biological entities, exosomes are highly compatible with the host immune system. They exhibit significantly lower immunogenicity and toxicity compared to synthetic LNPs or viral vectors, making them ideal for repeated systemic administrations. -
Protection Against Degradation
The robust lipid bilayer completely shields the encapsulated RNAi payload from RNase degradation in the extracellular environment and blood circulation. -
Favorable Pharmacokinetics
Exosomes possess an optimal particle size (40-120 nm) and a slightly negative surface charge (zeta potential). This allows them to evade rapid renal clearance and minimizes unspecific phagocytosis by the mononuclear phagocyte system (MPS), thereby extending their half-life in blood circulation. -
Intrinsic Homing and Targeting Capabilities
Depending on their cellular origin (e.g., dendritic cells, mesenchymal stem cells, or tumor cells), exosomes exhibit natural tropism and homing capabilities. This natural targeting can be further enhanced through precision surface engineering. -
Crossing the Blood-Brain Barrier (BBB)
Unlike many traditional vectors, specific exosomes have demonstrated the remarkable ability to cross the BBB, opening new frontiers for treating central nervous system (CNS) disorders with RNAi. -
Efficient Intracellular Delivery
Exosomes facilitate highly efficient cellular entry through various mechanisms, including endocytosis, macropinocytosis, and direct membrane fusion, ensuring the functional delivery of RNAi into the recipient cell's cytoplasm where the RNA-induced silencing complex (RISC) operates.
Exosomes vs. Traditional Gene Delivery Vectors
| Features | Exosomes (Natural Nanocarriers) | Traditional Vectors (Viral Vectors & LNPs) |
|---|---|---|
| Immunogenicity (vs. Viral Vectors) | Effectively circumvent immune bottlenecks (especially autologous/hypoimmunogenic exosomes), allowing for repeated dosing. | Viral Vectors: Adenoviral and AAV vectors can elicit strong neutralizing antibody responses, severely limiting repeated dosing. |
| Safety Profile (vs. Viral Vectors) | Delivers RNAi directly to the cytoplasm, entirely eliminating the risk of genomic alteration. | Viral Vectors: Lentiviral vectors carry the inherent risk of insertional mutagenesis due to genomic integration. |
| Payload Capacity (vs. Viral Vectors) | Highly flexible; can multiplex distinct siRNAs, miRNAs, or co-load with small molecule drugs for synergistic therapies. | Viral Vectors: Strict packaging limits (e.g., ~4.7 kb for AAV) restrict cargo size. |
| Toxicity (vs. LNPs) | Entirely natural lipid composition that is inherently non-toxic and highly biocompatible. | LNPs: Cationic or ionizable lipids can induce cytotoxicity and inflammatory responses, particularly in sensitive tissues like the liver. |
| Targeting Complexity (vs. LNPs) | Precision targeting to the brain, tumors, or specific immune cells is achievable through natural tropism and advanced surface display technologies. | LNPs: Predominantly accumulate in the liver (hepatotropism); redirecting them to extrahepatic tissues remains a significant bioengineering hurdle. |
Creative Biolabs' Custom Exosomes Service for RNAi
Creative Biolabs provides tailored exosome-mediated RNAi delivery services for academic, biotechnology, pharmaceutical, and translational research clients. Our service is not limited to a single protocol. Instead, we build project-specific workflows based on the RNAi molecule, target cell type, disease model, delivery route, required scale, and downstream functional readout.
Our custom exosome service may include:
| Services | Description |
|---|---|
| Exosome Source Selection | Selection of suitable donor cells or biological sources based on project needs, compatibility, scalability, and target application. |
| Exosome Production | Culture and conditioning of donor cells under optimized conditions to generate exosome-containing media. |
| Isolation and Purification | Enrichment and purification of exosomes using appropriate methods to support downstream characterization and functional studies. |
| RNAi Cargo Loading | Development of loading strategies for siRNA, miRNA mimics, or other RNAi molecules. |
| Surface Targeting Modification | Optional engineering or modification of exosomes with targeting peptides, ligands, antibodies, or other molecules. |
| Characterization and QC | Analysis of particle size, concentration, morphology, marker expression, cargo association, purity, and stability. |
| In Vitro Functional Testing | Evaluation of cellular uptake, target gene knockdown, cytotoxicity, and biological activity in relevant cell models. |
RNAi Cargo Loading Strategies at Creative Biolabs
Efficient loading of RNAi molecules into or onto exosomes is a key determinant of delivery performance. Creative Biolabs develops customized loading strategies based on the cargo type, exosome source, downstream application, and analytical requirements.
Passive Incubation
Passive incubation is a relatively simple method in which RNAi molecules are mixed with exosomes under defined conditions. This approach may be suitable for feasibility studies, early screening, or projects where mild processing is preferred.
Electroporation-Based Loading
Electroporation can promote RNA entry into exosomes by transiently permeabilizing the vesicle membrane. This method is often evaluated when higher loading efficiency is required, although process conditions must be carefully optimized to minimize aggregation or vesicle damage.
Chemical or Reagent-Assisted Loading
Certain reagent-assisted methods may enhance association between RNAi molecules and exosomes. Creative Biolabs can evaluate reagent compatibility, loading efficiency, residual reagent control, and downstream biological impact.
Donor Cell Engineering
In some cases, donor cells can be engineered or treated to enrich desired RNA cargo in secreted exosomes. This strategy may be useful when researchers want biologically produced RNA-loaded exosomes or when direct post-isolation loading is not optimal.
Hybrid Loading Strategies
For complex projects, Creative Biolabs can compare multiple loading strategies side by side. This allows clients to identify the best balance among cargo loading, vesicle integrity, purity, stability, and functional gene silencing.
Targeted Exosome Design for RNAi Delivery
For many RNAi applications, delivery specificity is as important as knockdown potency. Non-selective uptake can reduce therapeutic index, increase off-target effects, and complicate interpretation of biological results. Creative Biolabs offers targeted exosome development strategies to improve cell-type or tissue-relevant delivery.
01 Targeted Exosome Design for RNAi Delivery
Creative Biolabs offers targeted exosome development strategies to improve cell-type or tissue-relevant delivery.
02 Peptide-Modified Exosomes
Creative Biolabs has explored peptide-targeted exosomes for targeted siRNA delivery.
03 Ligand-Based Targeting
Ligands that bind cell surface receptors may be incorporated into exosome design strategies.
04 Antibody or Antibody Fragment-Mediated Targeting
These systems can be designed to recognize tumor markers, immune receptors, or disease-associated surface proteins.
05 Source-Driven Tropism
Creative Biolabs can help clients evaluate whether source-derived tropism contributes to delivery selectivity and whether additional engineering is needed.
06 Comparative Targeting Evaluation
When the optimal targeting strategy is uncertain, we can design comparative studies to evaluate multiple exosome designs in parallel.
Analytical Characterization and Quality Control
Our characterization options may include:
| QC Category | Representative Analyses |
|---|---|
| Particle Size | Nanoparticle tracking analysis, dynamic light scattering, or equivalent size distribution methods |
| Particle Concentration | Quantification of vesicle particle number or particle-to-protein ratio |
| Morphology | Electron microscopy or imaging-based evaluation where applicable |
| Exosome Markers | Detection of exosome-associated protein markers |
| Purity Assessment | Evaluation of protein contaminants, nucleic acid impurities, or non-vesicular particles |
| Cargo Loading | Quantification of RNAi cargo association, encapsulation, or recovery |
| Stability | Assessment under storage, handling, or formulation conditions |
| Uptake Assay | Fluorescent labeling or other cell-based uptake analysis |
| Functional Potency | Target mRNA knockdown, protein reduction, or pathway modulation |
| Safety-Related Readouts | Cell viability, cytotoxicity, inflammatory response markers, or tolerability assays |
What You Receive
Creative Biolabs provides more than a prepared exosome sample. Our goal is to deliver a scientifically useful and development-oriented package that helps clients make informed decisions. Depending on the selected service scope, clients may receive:
- Customized exosome preparations generated from selected donor cells or project-specific sources.
- RNAi-loaded exosome formulations prepared using optimized or comparative loading methods.
- Targeted exosome designs incorporating peptide, ligand, antibody fragment, or other targeting strategies when required.
- Characterization data covering particle size, concentration, morphology, marker analysis, loading efficiency, purity, and stability.
- In vitro functional results including cellular uptake, target gene knockdown, cytotoxicity, and biological response assays.
- Comparative screening data for different exosome sources, loading strategies, targeting designs, or RNAi cargo formats.
- In vivo support data where applicable, including biodistribution, tissue exposure, tolerability, and gene silencing readouts.
- A detailed final report summarizing experimental methods, quality control results, assay outcomes, interpretation, and recommended next steps.
Frequently Asked Questions (FAQ)
Q: What types of RNAi molecules can be delivered using your custom exosome service?
A: Creative Biolabs can support exosome delivery studies involving siRNA, miRNA mimics, anti-miRNA oligonucleotides, and other RNAi-related molecules. The exact cargo format depends on the target gene, disease model, desired duration of silencing, and downstream assay requirements. We can also evaluate chemically modified RNAi molecules when stability or delivery performance is a concern.
Q: Can you help select the best exosome source for my project?
A: Yes. Exosome source selection is one of the most important design steps. We consider the target cell type, disease context, donor cell compatibility, scalability, safety considerations, and expected uptake behavior. If the optimal source is unknown, we can design a comparative study using multiple exosome sources.
Q: How do you load siRNA into exosomes?
A: Several approaches may be used, including passive incubation, electroporation-based loading, reagent-assisted loading, donor cell engineering, or hybrid strategies. The best method depends on the siRNA properties, exosome source, desired loading level, and downstream functional requirements. Creative Biolabs can optimize or compare loading methods for each project.
Q: Can exosomes be modified for targeted delivery?
A: Yes. Exosomes can be modified or engineered with targeting peptides, ligands, antibody fragments, or other surface elements to improve uptake by specific cell types. The original service page also highlights peptide-targeted exosomes for targeted siRNA delivery. We can help design and evaluate targeting strategies based on your receptor or cell-type requirements.
Q: What quality control data can you provide?
A: Depending on project scope, we can provide data on particle size, concentration, morphology, exosome marker expression, purity, RNAi cargo loading, stability, cellular uptake, target gene knockdown, and cytotoxicity. For advanced projects, additional functional or in vivo readouts can be included.
Q: Can you evaluate whether the RNAi-loaded exosomes actually silence my target gene?
A: Yes. Functional validation is a key part of our service. We can measure target mRNA reduction by qPCR, protein reduction by Western blot, ELISA, flow cytometry, or immunostaining, and downstream pathway or phenotype changes depending on the project design.
Request a Quote or Scientific Consultation
The therapeutic potential of exosome-mediated siRNA delivery system has been demonstrated in vitro, which gives additional evidence of the ability to use human exosomes in RNAi-based gene therapy. Experienced in the development of exosome-mediated delivery system for RNAi, Creative Biolabs has perfected our technical pipelines to offer high-quality custom exosome service for RNAi. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
- Lu Y, Huang W, Li M, et al. Exosome-based carrier for RNA delivery: progress and challenges. Pharmaceutics, 2023, 15(2): 598. https://doi.org/10.3390/pharmaceutics15020598 Distributed under Open Access license CC BY 4.0, without modification.
